Advertisement
Advertisement
U.S. Markets open in 6 hrs 41 mins
Advertisement
Advertisement
Advertisement
Advertisement

PTC Therapeutics, Inc. (PTCT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.33-0.17 (-0.52%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close32.50
Open32.83
Bid12.80 x 1100
Ask33.80 x 800
Day's Range31.44 - 33.47
52 Week Range30.03 - 45.80
Volume639,123
Avg. Volume566,876
Market Cap2.286B
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-6.50
Earnings DateMay 02, 2022 - May 06, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.11
  • Benzinga

    Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder

    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of PTC Therapeutics Inc's (NASDAQ: PTCT) Upstaza (eladocagene exuparvovec, PTC-AADC). Once ratified by the European Commission, Upstaza will be the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency for patients 18 months and older and the first marketed gene therapy directly infused into the brain. Related: PTC Therapeutics' Ra

  • PR Newswire

    PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec; PTC-AADC) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Once ratified by the European Commission, Upstaza will be the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency for patients 18 months and older and the first marketed gene therapy directly infused into the brain.

  • Zacks

    PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

    PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -14.84% and 2.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement